What are the recommended disease-modifying antirheumatic drugs (DMARDs) and their dosing for rheumatoid arthritis?

DMARD Recommendations for Rheumatoid Arthritis

Start methotrexate immediately as first-line DMARD therapy for all DMARD-naive patients with active rheumatoid arthritis 1, 2.

Initial Treatment Strategy

First-Line Therapy: Methotrexate

• Methotrexate is the anchor DMARD and should be initiated as soon as RA diagnosis is established 1, 2
• Methotrexate is strongly preferred over other conventional synthetic DMARDs (hydroxychloroquine, sulfasalazine, leflunomide) due to superior efficacy, safety profile, and flexibility in combination regimens 2
• Add short-term glucocorticoids when initiating methotrexate, then taper and discontinue as quickly as possible 1

Dosing considerations:

• Use effective doses of methotrexate (oral or subcutaneous) with folic acid supplementation 3
• Subcutaneous route may improve tolerability and efficacy if oral dosing is inadequate 4

Treatment Target Approach

• Aim for remission or low disease activity using a treat-to-target strategy 1, 2, 5
• Reassess disease activity within 3 months and modify treatment if target not achieved 2
• Monitor using validated disease activity measures (DAS28 or ACR-endorsed instruments) 2, 6

Escalation for Inadequate Response

If Methotrexate Monotherapy Fails (3-6 months)

For patients WITHOUT poor prognostic factors:

• Add triple conventional synthetic DMARD therapy (methotrexate + sulfasalazine + hydroxychloroquine) 1
• This controls symptoms in approximately one-third of patients 1

For patients WITH poor prognostic factors (positive autoantibodies, high disease activity, early erosions, or failure of 2 csDMARDs):

• Add a biologic DMARD to methotrexate 1, 5

• Biologic options include:

  • TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol)
  • IL-6 receptor inhibitors (tocilizumab, sarilumab)
  • T-cell costimulation inhibitor (abatacept)
  • Anti-CD20 antibody (rituximab - after TNF inhibitor failure) 2, 5

• Targeted synthetic DMARDs (JAK inhibitors) may be considered as alternatives: tofacitinib, baricitinib, upadacitinib, filgotinib 5

  • Important caveat: Carefully consider risks of major cardiovascular events (MACEs), malignancies, and thromboembolic events before using JAK inhibitors 5

If First Biologic/Targeted Synthetic DMARD Fails

Switch to any other biologic DMARD (from same or different class) or targeted synthetic DMARD 2, 5

• No specific class is preferentially recommended for second-line biologic therapy 6
• Biosimilars are considered equivalent to originator biologics 2

Special Populations and Comorbidities

Previous Serious Infection (within 12 months)

• Add conventional synthetic DMARDs rather than biologics/targeted synthetic DMARDs 2
• Prioritize DMARD addition/switching over glucocorticoid escalation 2

Nontuberculous Mycobacterial Lung Disease

• Use lowest possible glucocorticoid dose (discontinue if possible) 2
• Add conventional synthetic DMARDs over biologics/targeted synthetic DMARDs 2
• If biologic needed, prefer abatacept over other biologics 2

RA-Associated Interstitial Lung Disease

• Exercise caution with certain DMARDs; specific recommendations require individualized risk-benefit assessment 2

Tapering in Sustained Remission

If patient achieves sustained remission (≥6 months at target):

• Taper DMARDs gradually by lowering dose or increasing dosing interval 2, 5
• Do not completely stop DMARDs - maintain some level of therapy 5
• Eight guidelines support tapering biologics after sustained good responses 6

Key Algorithmic Approach

1. Start: Methotrexate + short-term glucocorticoids → taper steroids
2. At 3 months: Assess disease activity
   • If at target → continue, monitor
   • If not at target → proceed to step 3
3. Stratify by prognostic factors:
   • Good prognosis: Add triple csDMARD therapy
   • Poor prognosis: Add biologic DMARD or JAK inhibitor (consider cardiovascular/malignancy risks)
4. If inadequate response: Switch to different biologic/JAK inhibitor
5. If sustained remission ≥6 months: Taper (but don't stop) DMARDs

Critical Pitfalls to Avoid

• Don't delay DMARD initiation - start immediately upon diagnosis 1, 3
• Don't use prolonged glucocorticoid therapy - taper quickly after DMARD initiation 1
• Don't stop monitoring - reassess every 3 months until target achieved 2
• Don't completely discontinue DMARDs even in sustained remission - taper only 5
• Don't ignore cardiovascular/malignancy risk when selecting JAK inhibitors 5

The most recent high-quality evidence from the 2026 PANLAR guidelines 1 and 2022 EULAR update 5 strongly supports this methotrexate-first, treat-to-target approach with systematic escalation based on prognostic factors and treatment response.